价格

PFIZER AUSTRALIA PTY LTD

LEVEL 15 135-151 CLARENCE STREET, Sydney, New South Wales, 澳大利亚

别名:

asasha

概览

试验阶段分布

阶段

试验数

占比

不适用

100.0%

试验状态分布

已完成

50.0%

终止

50.0%

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

TGA

Therapeutic Goods Administration

950

药物批准

SFDA

Saudi Food and Drug Authority

药物批准

近期批准

Irinotecan Hydrochloride Injection

NMPA

2025-12-10

Irinotecan Hydrochloride Injection

NMPA

2025-12-10

Irinotecan Hydrochloride Injection

NMPA

2025-12-10

COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection multidose vial (506527)

TGA

2025-10-01

COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 3 micrograms/0.3 mL concentrated suspension for injection multidose vial (506534)

TGA

2025-10-01

COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection vial (506526)

TGA

2025-10-01

COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection multidose vial (506507)

TGA

2025-10-01

COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection prefilled glass syringe (506536)

TGA

2025-10-01

COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 3 micrograms/0.3 mL concentrated suspension for injection multidose vial (506534)

TGA

2025-10-01

COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection prefilled glass syringe (506536)

TGA

2025-10-01

资讯

暂无资讯文章

返回机构列表

PFIZER AUSTRALIA PTY LTD

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（2）

Assessing the IMpact of Alopecia Areata (AA) on PatIents’ and CaregiverS’ in Australia (MARISSA)

Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Patients Treated with Palbociclib for Advanced Breast Cancer in Australia (PIPPA)

药物批准

按机构分类的批准

近期批准

资讯